I
In Ovo
Gender screening technology to improve efficiency of the poultry industry
About In Ovo
In Ovo is a biotechnology company focused on the poultry industry, specifically addressing the widespread practice of culling day-old male chicks. The company was formally established in 2013 as a spin-off from Leiden University by founders Wouter Bruins, a biologist, and Wil Stutterheim, a biomedical scientist. Their journey began in 2011 during a science-based business master's course at the university, where an interview with a poultry farmer highlighted chick culling as a significant ethical and operational problem in the sector. This insight prompted them to develop a business case around a technological solution, leveraging the resources of the Leiden Bio Science Park.
In Ovo's core business revolves around its proprietary technology, the 'Ella' machine, which provides a high-throughput, automated solution for determining the gender of eggs early in the incubation process. This in-ovo sexing technology works by extracting a minuscule fluid sample from the egg on day nine of incubation and analyzing it for a specific gender biomarker using mass spectrometry. The entire process is automated, takes less than a second per egg, and achieves over 98% accuracy. By identifying male eggs before the embryo develops significantly, hatcheries can remove them from the incubation process, thus preventing the birth and subsequent culling of male chicks. This addresses a major animal welfare concern, as an estimated 6.5 billion male chicks are culled annually worldwide.
The company's business model targets commercial poultry hatcheries, offering them the Ella system as a fully integrated, inline solution that has a minimal footprint and can be incorporated into existing operations. In Ovo installs and services the machines, creating value for its clients by improving animal welfare, meeting regulatory requirements and consumer demand for ethical products, and increasing operational efficiency. Preventing the incubation of male eggs reduces energy consumption and CO2 emissions. Discarded male eggs can be repurposed as a byproduct for other industries, such as animal feed or protein powders. The company has received significant financial backing, including multiple funding rounds from investors like Evonik Venture Capital and VisVires New Protein, and a €40 million loan from the European Investment Bank to accelerate international expansion.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Employees
- 10
- Open positions
- None listed
- Sub-industry
- AgriTech
- Sector
- Testing, Biotechnology, Poultry, Biochemical, Chicken, Spinout, Mass Spectrometry, Primary Production, iSensing & Robotics, EIC
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBT✓Debt | Nov 2023 | $44M | — | European Investment Bank | ↗ |
| SERIES B✓Equity / VC | Mar 2022 | $37M | $150M | Clay Capital · European Circular Bioeconomy Fund · Evonik Venture Capital · Demcon | ↗ |
Growth signals
Latest recorded traffic for In Ovo is 390 monthly website visits, up 8.3% over the last three months. In Ovo's team declined 37.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
In Ovo in the Leiden ecosystem
The In Ovo office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A5 investors entered at this stage
Evonik Venture Capital
Clay Capital
European Circular Bioeconomy Fund
Demcon
ABN AMRO Ventures
Series B and later1 investor entered at this stage
European Investment Bank
Other known investors5 additional known investors
Leiden University
ABN AMRO
Libertatis Ergo Holding
Rabobank
Unlock
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about In Ovo on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See In Ovo’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










